WASHINGTON – American Forest & Paper Association President and CEO Donna Harman issued the following statement in response to the Food and Drug Administration (FDA) publishing its e-labeling rule for prescription drugs.
“We’re disappointed that the FDA has chosen to all but eliminate the option of having printed information for prescription drugs available to healthcare professionals. E-labeling should not totally replace paper inserts. A July 2013 GAO report concluded that relying exclusively on electronic labeling could disadvantage physicians, pharmacists, other healthcare providers, and ultimately patients, potentially adversely impacting public health. Furthermore, FDA’s proposal goes against congressional intent, which was most recently made clear in the House and Senate-passed funding bill.
“We appreciate Sens. Mark Pryor (D-AR), Susan Collins (R-ME), and Lamar Alexander (R-TN) for their leadership on this issue, and we will continue to work with Congress, FDA, and other stakeholders to ensure that Americans who are affected by the availability of this information are not disadvantaged by such a move.”